Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda Pharmaceutical Company Limited today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous induction therapy.

22 Oct 2018

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., today announced detailed results from the Phase III SOLO-1 trial testing LYNPARZA (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion for KALYDECO (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.

22 Oct 2018

Immunotherapy increases survival in some patients with metastatic triple negative breast cancer

Immunotherapy improves survival in some patients with metastatic triple negative breast cancer, according to late-breaking results from the IMpassion130 trial reported at the ESMO 2018 Congress in Munich.

22 Oct 2018

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Takeda Pharmaceutical Company Limited today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients.

22 Oct 2018

ApoE4 gene linked with chronic inflammation increases risk for Alzheimer's disease

While it is widely shown that possessing the ApoE4 gene is the major genetic risk factor of Alzheimer's disease, not all ApoE4 carriers develop AD.

20 Oct 2018

Could we prevent Alzheimer's disease by treating herpes?

An exciting new paper suggests that over half of all cases of Alzheimer’s disease could be traced back to herpes simplex virus 1, which causes cold sores.

19 Oct 2018

Understanding of metal-free enzymes used by bacteria could lead to new effective antibiotics

Some bacterial pathogens, including those that cause strep throat and pneumonia, are able to create the components necessary to replicate their DNA without the usually required metal ions.

19 Oct 2018

Newly developed synthetic DNA molecule may one day be used as 'vaccine' for prostate cancer

Researchers from City of Hope, a world-renowned comprehensive cancer center and independent biomedical research institution, have developed a synthetic DNA molecule that is programmed to jump-start the immune system to eradicate genetically distinct types of prostate cancer.

19 Oct 2018

UT Southwestern biochemist receives 2019 Breakthrough Prize in Life Sciences for innate immunity discovery

UT Southwestern biochemist Dr. Zhijian "James" Chen today was named winner of the prestigious 2019 Breakthrough Prize in Life Sciences for his discovery of the cGAS enzyme that launches the body's immune defense against infections and cancers.

19 Oct 2018

Scripps researchers successfully test potential new smoking-cessation treatment in rodents

Scientists at Scripps Research have successfully tested a potential new smoking-cessation treatment in rodents.

19 Oct 2018

New DNA vaccine strategy protects mice against lethal challenge by multiple H3N2 viruses

Researchers developed a novel DNA influenza vaccine based on four micro-consensus antigenic regions selected to represent the diversity of seasonal H3N2 viruses across decades.

18 Oct 2018

Cases of Acute Flaccid Myelitis on the rise across U.S.

According to the Centre for Disease Prevention and Control (CDC), cases of dangerous and rare Acute Flaccid Myelitis (AFM) are being noted across United States. This disease manifests similar to acute flaccid paralysis caused by polio virus say the experts. There is at present no treatment for this condition that primarily affects children and leads to paralysis of the limbs.

18 Oct 2018

Researchers propose skin hardness as physiological sign to estimate human thermal status

Under the same temperature and humidity, human thermal status may vary due to individual body constitution and climatic environment.

17 Oct 2018

Eisai enters into agreement with Eurofarma for development and sales of lorcaserin in 17 countries

Eisai Co., Ltd. has entered into an agreement to grant exclusive development and marketing rights for its anti-obesity agent lorcaserin hydrochloride (generic name, product name in the United States: BELVIQ, product name for once-daily formulation in the United States: BELVIQ XR, "lorcaserin") in 17 countries in Latin America and the Caribbean, excluding Brazil, to Eurofarma Laboratorios S.A. which has a business foundation in Latin America.

16 Oct 2018

Who knew? Life begins (again) at 65

I was convinced I would become an adult when I turned 21. But now, I'm certain that turning 65 was the watershed moment that finally grew me up.

15 Oct 2018

Many parents still skeptical about safety and effectiveness of flu shot, survey finds

When a child gets the flu, they're not only sick in bed for a week or more, but the illness can also have serious and even life-threatening consequences.

15 Oct 2018

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis

Immunotherapy increases survival in some patients with metastatic triple negative breast cancer

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

ApoE4 gene linked with chronic inflammation increases risk for Alzheimer's disease

Could we prevent Alzheimer's disease by treating herpes?

Understanding of metal-free enzymes used by bacteria could lead to new effective antibiotics

Newly developed synthetic DNA molecule may one day be used as 'vaccine' for prostate cancer

UT Southwestern biochemist receives 2019 Breakthrough Prize in Life Sciences for innate immunity discovery

Scripps researchers successfully test potential new smoking-cessation treatment in rodents

New DNA vaccine strategy protects mice against lethal challenge by multiple H3N2 viruses

Cases of Acute Flaccid Myelitis on the rise across U.S.

Researchers propose skin hardness as physiological sign to estimate human thermal status

Eisai enters into agreement with Eurofarma for development and sales of lorcaserin in 17 countries

Who knew? Life begins (again) at 65

Many parents still skeptical about safety and effectiveness of flu shot, survey finds

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

The importance of ketones from a clinical and medical perspective

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

The importance of ketones from a clinical and medical perspective

Newsletters you may be interested in